Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation

Recently, clinical development of PARP inhibitors (PARPi) expanded from using them as a single agent to combining them with DNA-damaging therapy to derive additional therapeutic benefit from stimulated DNA damage. Furthermore, inhibiting PARP in cancers with BRCA1/2 mutations has been shown to be an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Aaron, Menon, Vijay, Khan, Zubair, Alam, Asim, Litovchick, Larisa, Yakovlev, Vasily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423503/
https://www.ncbi.nlm.nih.gov/pubmed/30889466
http://dx.doi.org/10.1016/j.redox.2019.101169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423503/
https://www.ncbi.nlm.nih.gov/pubmed/30889466
http://dx.doi.org/10.1016/j.redox.2019.101169

Ejemplares similares